Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Intra-Cellular Therapies, Inc. (ITCI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
42.66+3.79 (+9.75%)
At close: 04:00PM EST
42.92 +0.26 (+0.61%)
After hours: 07:59PM EST
Advertisement
Sign in to post a message.
  • A
    Al
    Brokerage is supporting the $42 price ... they still have their 15% over allotment to short ... would be my guess esp that an almost 10% move should have some news &/or volume .... Great stock, but since a buyout is probably off the table for at least 6 months (due to the recent offering) ... $38ish or lower would be a much better entry point ... you can't fight the fed. .. if your holding for 12 months .. should be a $60 to $70 stock by then... my opinion
  • M
    Martin
    Weekly prescriptions jumped 20% week-to-week. Seems like the first insurances are now covering the new BP indication. Expect this trend to hold.
    Bold prediction: ITCI will go cash flow neutral in Q4 2022 ER!
    Bullish
  • S
    Surfin'
    What's behind the spike higher?
    I don 't see anything...??
    I bought at 38 yesterday but
    got scared out with bearish
    sentiment re biotech.
    Bullish
  • A
    Adam
    Todays volume on a big down market day may imply accumulation with possible buyout down the road
  • C
    Chicago J
    “Jan 13 - Sharon Mates Sells 41,896 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock”

    Thanks a lot, Dr. Sharon. You are a class act. Don’t worry, you can always print up some more shares and line your pockets. Please don’t concern yourself with the long term holders of the stock, who continue to get our shares diluted more and more. My shares have appreciated over the years, for sure, but they should be double what they are today. So maybe you hold onto your shares as a show of faith until you earn your keep and the stock price goes really high, huh?
  • C
    Clovus
    I just added more to the core portfolio at the $40 level. We know this stock is worth at least $42 to the fund managers so $40 and under seems to be a good buy at present.
    One of the few stocks with a decent option premium still available.
    Might look at selling $46 or $48 Covered Calls
    Bullish
  • A
    Anonymous
    I have been in ITCI for about 3 years now, after all that has been said here I still give 70-80% probability that ITCI will be taken over by the end of this year. Big pharma usually swallows up a company with approved drugs and one with a huge market (BP). IMO, do your own DD.
  • M
    Max
    DOUBLED DOWN AT $42.5

    $50 NEXT WEEK!

    GO ITCI!
    Bullish
  • G
    Giovanni
    The Company has now almost 850 M$ in cash, available for marketing caplyta with the new expanded label, and other activities. ITCI Future is bright and SP will soon get to 60+
  • A
    Al
    My take ... the brokerage handling the sale basically shorted this down yesterday knowing that they would get shares at less than the closing price ... easy free money for them at the expense of the share holders. It should have been a shelf offering that would be exercised from time to time ... would have taken 60 to 90 days to sell 9 mil (or 7 1/2 is they got in the 50's) new shares into the market ... nowhere near the 18% or so hit the PPS has currently taken. ... The Brokerage is now buying to pump up the price before reselling in volume ... don't get me wrong, GREAT RXs ... Buyout candidate in 1 to 2 years, or sooner .. for over $70 .. but at this point in time ... not really a reason to buy more above $42.
  • C
    Clovus
    My choice today was to sell some March covered calls or take profits on 60% of my holdings. With $11.23 profit and the balance sold at $50 for May I figured to protect the cash gain I can still buy the stock back when it drops below 39 again at earnings. Sold at $43.40
    I have a long memory and looked back June was the high in 2021 and it sold off from $44 to $28. I love this stock but the premiums have gone down even with todays spike so it seems the shorts are taking positions but not overpaying for calls.
    Untill this market makes sense again I am presently sitting on 21% cash.
    I am a buyer of ITCI below 39 if we ever get there again.
    If it continues to rally with no pull back so be it. Still have a large position with CCs attached.
    Neutral
  • C
    Clovus
    I said $43 to $45 I was off by $1 but it makes sense. You dilute the stock 14.3% when its at $50 - $52 the price should be $7.15 to 7.44 less.. I got $42.85 to $44.56 so my math was close. Forgot the other 1.5 million shares they can still subscribe too.

    All the same the option values two months out are holding premium so I will sell some more once we get over $48 again.

    The Analyst
  • D
    Dale
    Management incompetence for not pricing secondary early this morning.
    They could have easily received $48.00 and now we suffer the results of
    Their delay.
  • M
    Max
    the trend is our friend on ITCI!

    BACK TO $50+ NEXT WEEK!

    GO ITCI!
    Bullish
  • M
    Max
    It’s taking off again

    Back to $40 then $50

    FDA approved drug

    Go ITCI
  • A
    Anonymous
    The big move this morning, IMO, is nothing but options related. Largest number of open interests for today's expiration are for calls and puts strike prices at 40. it is called Maximum Pain!! Most likely the stock will close around 40 today. Just my opinion, long ITCI, Do your own DD.
  • M
    Matt
    But still, a 25+% haircut from our high of $55 seems a bit of an over-correction.
  • F
    FishmasterM
    closing the offering quickly is good- if institutions really thought it was a bad deal then I'm sure it would have taken longer or not closed at all- raising capital on the heels of great news is also good-
  • R
    Roland
    Considering a buy-write here to get in well below the underwriters.

    Buy for $39.60 and sell the Feb $43 calls for $2, so net $37.60?
  • B
    Bradley
    Canaccord Genuity, analyst Sumant Kulkarni sees the multiplicity of paths forward as the key point, writing, “With this clean label, i.e., Caplyta is now approved as mono/adjunct therapy for adults with depressive episodes in Types 1 and 2 bipolar disorder, we believe ITCI is positioned well to drive home the product's advantages... We continue to believe ITCI remains significantly undervalued on the opportunity in schizophrenia/bipolar depression. We note most investor focus has been around Caplyta's launch so far and this sNDA action date. But, the company also has a strong pipeline that not only includes further extensions of its Caplyta franchise, but also other new molecules in development…”

    Kulkarni's upbeat outlook leads him to put a Buy rating on ITCI, and his price target, of $88, implies an upside of 76% for the year ahead.
Advertisement
Advertisement